Neurodon Announces Initiation of Investigational New Drug (IND)-Enabling Studies for NDC-0009, a Novel Small Molecule for the Treatment of Type 1 Diabetes (T1D)
Retrieved on:
Monday, May 17, 2021
Science, Research, Pharmaceutical, General Health, Health, FDA, Diabetes, Clinical trials, Clinical research, Drug Safety, Food and Drug Administration, Investigational New Drug, Health, NDC-0009 and Neurodon’s Drug Candidates, Type 1 Diabetes, Neurodon, NDC-0009 AND NEURODON’S DRUG CANDIDATES, TYPE 1 DIABETES, NEURODON
b"Neurodon Corporation today announced the initiation of essential studies necessary to enable preparation of an Investigational New Drug (IND) application for the U.S. Food and Drug Administration (FDA) for NDC-0009, a novel molecule to treat T1D.
Key Points:
- b"Neurodon Corporation today announced the initiation of essential studies necessary to enable preparation of an Investigational New Drug (IND) application for the U.S. Food and Drug Administration (FDA) for NDC-0009, a novel molecule to treat T1D.
- Neurodon aims to initiate clinical trials in the second half of 2022.\n\xe2\x80\x9cWe are excited to achieve this milestone with the selection of a development candidate for our diabetes program.
- Resulting glucotoxicity is responsible for accompanying maladies such as kidney disease, vision loss, nerve disease, heart disease, and death.
- Neurodon deploys its proprietary ER stress-based technology platform to discover compounds that target the root cause of disease.